RegulationVitalspan Wire conceptual illustrationFDA redraws the development path for 17 generic peptide products
Authoritative regulatory record indexed on 2026-07-28, with the claim calibrated to evidence grade A.
VOL. 01AUGUST 2026
The NewsroomMenu
Regulation
FDA actions, compounding policy, enforcement and the rules shaping patient access.
RegulationVitalspan Wire conceptual illustration
RegulationVitalspan Wire conceptual illustrationEpitalon’s longevity reputation meets FDA’s compounding test
Authoritative regulatory record indexed on 2026-07-24, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationSemax compounding review puts neuropeptide claims against the federal record
Authoritative regulatory record indexed on 2026-07-24, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationFDA reviews emideltide claims for sleep disorders and opioid withdrawal
Authoritative regulatory record indexed on 2026-07-24, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationMOTS-c and TB-500 face the evidence standards of FDA compounding review
Authoritative regulatory record indexed on 2026-07-23, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationKPV enters FDA advisory review with wound-healing claims under scrutiny
Authoritative regulatory record indexed on 2026-07-23, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationFDA panel takes up BPC-157 as compounding evidence comes under review
Authoritative regulatory record indexed on 2026-07-23, with the claim calibrated to evidence grade A.
RegulationVitalspan Wire conceptual illustrationFDA revises its playbook for 17 generic peptide drugs
The agency's new product-specific drafts sharpen the scientific path for evaluating complex peptide generics. Here is what changed—and what did not.
RegulationVitalspan Wire conceptual illustrationWhat 'compounded' means—and what it does not mean
A practical guide to approval, quality review and the circumstances in which clinicians may turn to compounded medicine.